智通财经11月13日讯（编辑 胡家荣）本周港股三大指数涨幅不一。截至收盘，恒生指数累计涨1.26%，报26572.46点；科技指数累计跌0.42%，报5812.80 点；国企指数累计涨1.41%，报9397.96点。 注：恒生指数的本周表现 从本周来看，恒生指数周一至周四震荡上行，但周五受外围市场拖累出现回调。 为何港股本周持续震荡？ 港股市场波动与外围环境密切相关。美国政府停摆期间，财政支出几近停滞，而税收等资金持续流入TGA账户，形成"只进不出"局面，导致近万亿美元流动 性被暂时锁定。这一情况推高了美元资金成本，并对美股、港股等风险资产形成压制。 不过，西部证券最新研究报告指出，随着美国政府结束停摆，此前被"冻结"的美元流动性有望释放，港股或迎来一轮流动性驱动行情。 此外，南向资金持续提供强劲支撑：内地资金通过港股通持续流入，年内净买入额已突破1.3万亿港元，累计规模超5万亿港元，成为市场构筑坚实支撑。南 向资金成交占比在港股市场已超过三成，定价权显著增强，港股正从外资主导的离岸市场，逐步转变为更多由内资定价的"半在岸市场"。 市场资金回流医药股 截至收盘，中国黄金国际(02099.HK)跌3.94%、紫 ...

消息面上，中金公司发研报指，"十五五"规划中提出"支持创新药和医疗器械发展"，再次印证创新药在 国计民生中的重要地位。我们认为国产创新药正从此前多年的"跟随式创新"中，通过沉淀积累从量变转 为质变，逐渐走出一批"后来居上"、乃至"同类最佳"、"全球首创"的优质管线。 来源：金吾财讯 金吾财讯 | 创新药概念股逆市走强，截至发稿，歌礼制药-B(01672)涨8.82%，金斯瑞生物科技(01548)涨 4.60%，翰森制药(03692)涨3.69%，康诺亚-B(02162)涨3.85%，先声药业(02096)涨2.55%。 中泰国际表示，医药行业创新药出海近期捷报频出，翰森制药将授权罗氏旗下企业抗体偶联物HS- 20110在除大中华地区以外的全球独占许可，信达生物(01801)将与武田药品(4502 JP)携手推进新一代肿 瘤免疫疗法(IO)及抗体偶联物(ADC)的研发。维立志博(09887)将授予美国药企Dianthus(DNTH US)在大 中华地区以外的研发、生产及商业化自身免疫药物LBL-047的权利。该机构认为，翰森制药的合作方罗 氏为全球著名的行业巨头，在ADC研发方面经验丰富，因此HS-20110的 ...

Market Overview - The Hang Seng Index fell by 1.26%, down 340 points, closing at 26,732 points, while the Hang Seng Tech Index dropped by 2.20% [1] - Early trading volume in the Hong Kong stock market reached HKD 125 billion [1] Hydrogen Energy Sector - The hydrogen energy sector experienced significant gains following the National Energy Administration's encouragement of green hydrogen utilization in coal chemical projects [1] - Reshaping Energy (02570) surged over 55% [1] - Guofu Hydrogen Energy (02582) rose over 11% [1] - Guohong Hydrogen Energy (09663) increased by over 5% [1] - Yihua Tong (02402) saw a rise of 6.8% [1] Pharmaceutical Sector - Basestone Pharmaceuticals-B (02616) increased by over 14% as GIC continued to increase its stake, surpassing 7% ownership [1] - Gilead Sciences (01672) rose over 14%, marking five consecutive days of gains, as it develops ASC36 into a monthly therapy [1] - Laika Pharmaceuticals-B (02105) gained 11.96% after securing a significant BD order worth CNY 2.045 billion for a breast cancer target [1] - Yu Yuan Group (00551) rose over 4% due to an increase in shoe prices and potential market share expansion through overseas capacity growth [1] - JS Global Life (01691) increased by 3.5% as a new product from Joyoung became popular, leading to a two-day stock limit increase for Joyoung Co., Ltd. (002242.SZ) [1] - JD Health (06618) rose by 6.8% post-earnings, with a year-on-year operating profit increase of over 125% and strategic partnerships with several well-known pharmaceutical companies [1] Technology Sector - The Hang Seng Tech Index followed the Nasdaq's decline, dropping over 2% [1] - Alibaba fell by 3.46% [1] - Tencent dropped by 0.91% post-earnings [1] Cryptocurrency Sector - Cryptocurrency-related stocks declined, with Boya Interactive (00434) falling over 5% as Bitcoin dropped below the USD 100,000 mark [2]

歌礼制药(01672)涨超5%暂现五连阳，本周累计涨幅已超30%。截至发稿，涨5.55%，报12.56港元，成 交额1819.48万港元。 消息面上，歌礼制药发布公告，每月一次新一代胰淀素受体激动剂ASC36和每月一次新一代GLP- 1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国FDA递 交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请。 分析人士指出，ASC36与ASC35为专有的超长效复方制剂，具有优越的理化稳定性，在中性pH值附近 没有纤维化导致的聚集沉淀。歌礼正将ASC36打造为每月一次疗法的基石，用于治疗包括肥胖在内的心 脏代谢疾病。ASC36有望达到比GLP-1疗法更优的疗效和耐受性，是一款既可作为单药疗法，也可与其 他长效制剂如ASC35或THRβ激动剂ASC47开发成复方制剂的理想候选药物。 ...

分析人士指出，ASC36与ASC35为专有的超长效复方制剂，具有优越的理化稳定性，在中性pH值附近 没有纤维化导致的聚集沉淀。歌礼正将ASC36打造为每月一次疗法的基石，用于治疗包括肥胖在内的心 脏代谢疾病。ASC36有望达到比GLP-1疗法更优的疗效和耐受性，是一款既可作为单药疗法，也可与其 他长效制剂如ASC35或THRβ激动剂ASC47开发成复方制剂的理想候选药物。 智通财经APP获悉，歌礼制药(01672)涨超5%暂现五连阳，本周累计涨幅已超30%。截至发稿，涨 5.55%，报12.56港元，成交额1819.48万港元。 消息面上，歌礼制药发布公告，每月一次新一代胰淀素受体激动剂ASC36和每月一次新一代GLP- 1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国FDA递 交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请。 ...

Group 1: Solar and Energy Stocks - Solar stocks showed recovery with New Special Energy (01799) up 4.99%, Flat Glass (06865) up 3.25%, Xinyi Solar (00968) up 3.75%, and GCL-Poly Energy (03800) up 2.27%. The China Photovoltaic Industry Association stated that rumors about a polysilicon storage platform were false, aiming to malign the industry [1][2] - Energy storage concept stocks rose against the trend, with Longpan Technology (02465) up 17.09%, Ruipu Lanjun (00666) up 15.2%, and Zhongxin Innovation (03931) up 9.22%. Lithium hexafluorophosphate prices have surged, with some market quotes reaching 150,000 yuan/ton, doubling since mid-October [1] Group 2: Oil and Gas Stocks - Oil stocks collectively declined, with CNOOC (00883) down 3.14%, CNOOC Services (02883) down 2.98%, PetroChina (00857) down 2.09%, and Sinopec (00386) down 1.79%. OPEC's monthly report indicated a slight oversupply in the oil market by 2026, contrasting previous predictions of sustained demand [2] Group 3: Steel and Mining Stocks - Steel stocks saw a midday surge, with Maanshan Iron & Steel (00323) up 7.09%, Ansteel (00347) up 2.26%, and Chongqing Iron & Steel (01053) up 2.13%. The Simandou project in Guinea, which has the potential to become the fifth-largest mine globally, has commenced production [2] Group 4: Airline and Transportation Stocks - Southern Airlines (01055) rose over 3.9% after reporting a 2.2% year-on-year increase in revenue for the first three quarters of 2025 [2] Group 5: Biotechnology and Pharmaceuticals - Gilead Sciences (01672) increased over 5.7% as it announced the clinical development of new drugs ASC36 and ASC35 [3] - Zai Lab (02509) rose over 8.4% after announcing plans for continued related transactions for the commercialization of QX001S from 2026 to 2028 [4] Group 6: Gold Stocks - Gold stocks collectively rose, with China Gold International (02099) up 5.99%, Jihai Resources (02489) up 7.3%, and Lingbao Gold (03330) up 4.47%. Gold prices have surpassed $4,100 and are testing the $4,200 resistance level [4] Group 7: US Market Movements - Major tech stocks in the US fell, with Meta Platforms (META.US) down over 2.8%, Tesla (TSLA.US) down over 2%, and Amazon (AMZN.US) down over 1.9% [5] - Eli Lilly (LLY.US) rose 2.95%, reaching a historical high, after announcing a deal to lower GLP-1 drug prices to $245 per month, potentially opening a new market of 30 million people [5] - The US airline service sector saw gains, with United Airlines (UAL.US) up 5.29% and American Airlines (AAL.US) up 3.62%, as the government is expected to reopen soon [5] Group 8: Nuclear Energy Stocks - US nuclear energy stocks rose, with Oklo (OKLO.US) up 6.67% as the government plans to finance new nuclear power plants to meet the energy demands of AI development [6] Group 9: Company-Specific Developments - On Holding (ONON.US) surged over 17.9% after reporting Q3 net sales of 794.4 million Swiss francs, exceeding market expectations [7] - AMD (AMD.US) rose 9% as it projected a 35% annual growth rate in revenue over the next three to five years, driven by AI chip demand [7]

"基于这些令人振奋的临床前数据，我们认为ASC36和ASC35复方制剂有望在肥胖人群中实现比单药疗 法更显著的减重效果。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"日益增多的成果证明 了歌礼的平台技术在设计、优化及开发多款每月一次皮下注射超长效多肽方面的能力。" 歌礼制药(01672)再涨超4%，截至发稿，涨3.55%，报11.68港元，成交额853.57万港元。 消息面上，歌礼制药公布，每月一次新一代胰淀素(amylin)受体激动剂ASC36和每月一次新一代GLP- 1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国食品药 品监督管理局(FDA)递交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请(IND)。 ...

智通财经APP获悉，歌礼制药(01672)再涨超4%，截至发稿，涨3.55%，报11.68港元，成交额853.57万港 元。 消息面上，歌礼制药公布，每月一次新一代胰淀素(amylin)受体激动剂ASC36和每月一次新一代GLP- 1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国食品药 品监督管理局(FDA)递交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请(IND)。 "基于这些令人振奋的临床前数据，我们认为ASC36和ASC35复方制剂有望在肥胖人群中实现比单药疗 法更显著的减重效果。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"日益增多的成果证明 了歌礼的平台技术在设计、优化及开发多款每月一次皮下注射超长效多肽方面的能力。" ...

在头对头饮食诱导肥胖(DIO)大鼠研究中，ASC36单药的减重效果较eloralintide单药相对提升约32%，而 在头对头DIO小鼠研究中，ASC35单药的减重效果较替尔泊肽单药相对提升约71%。在头对头DIO大鼠 研究中，ASC36和ASC35复方制剂的减重效果较eloralintide和替尔泊肽复方制剂相对提升约51%。 "基于这些令人振奋的临床前数据，我们认为ASC36和ASC35复方制剂有望在肥胖人群中实现比单药疗 法更显著的减重效果。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"日益增多的成果证明 了歌礼的平台技术在设计、优化及开发多款每月一次皮下注射超长效多肽方面的能力。" 歌礼制药-B(01672)发布公告，每月一次新一代胰淀素(amylin)受体激动剂ASC36和每月一次新一代GLP- 1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国食品药 品监督管理局(FDA)递交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请(IND)。 每月一次新一代胰淀素受体激动剂ASC36与每月一次新一代GLP-1R/GIPR双靶点激动剂A ...

智通财经APP讯，歌礼制药-B(01672)发布公告，每月一次新一代胰淀素(amylin)受体激动剂ASC36和每 月一次新一代GLP-1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二 季度向美国食品药品监督管理局(FDA)递交 ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申 请(IND)。 每月一次新一代胰淀素受体激动剂ASC36与每月一次新一代GLP-1R/GIPR双靶点激动剂ASC35均由歌礼 利用其AI辅助药物发现(Artificial IntelligenceAssisted Structure-Based Drug Discovery，AISBDD)与超长效 药物开发平台(Ultra-Long-Acting Platform，ULAP)技术自主研发而成。凭借ULAP技术，歌礼已成功将 ASC36与ASC35制成专有的超长效复方制剂，以实现每月一次皮下给药。ASC36和ASC35复方制剂具有 优越的理化稳定性，在中性pH值附近没有纤维化导致的聚集沉淀。一些胰淀素受体激动剂多肽会在中 性pH值附近出现聚集沉淀，会导致药效减弱、出现浑浊╱颗粒、装置堵 ...